<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03837509</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 01158-206</org_study_id>
    <nct_id>NCT03837509</nct_id>
  </id_info>
  <brief_title>INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>A Randomized Open-Label Phase 1/2 Study of INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Participants With Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and antitumor activity of INCB001158 in&#xD;
      combination with daratumumab SC, compared with daratumumab SC alone, in participants with&#xD;
      relapsed or refractory multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    This decision follows recruitment difficulties. No safety related concerns impacted this&#xD;
    decision.&#xD;
  </why_stopped>
  <start_date type="Actual">September 25, 2019</start_date>
  <completion_date type="Actual">June 29, 2021</completion_date>
  <primary_completion_date type="Actual">June 29, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>An initial equal randomization of participants between INCB001158 in combination with daratumumab SC (Treatment Group A), daratumumab SC monotherapy (Treatment Group B), and INCB001158 monotherapy (Treatment Group C) will be conducted. Participants in the treatment groups B and C at confirmed disease progression will be crossed over to INCB001158 + daratumumab SC. After the equal randomization period, a response adaptive randomization design will be used to compare the objective response rate of Treatment Groups A and B with adjustments to the randomization rate based on the observed objective response rate.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Number of treatment-emergent adverse events with INCB001158 in combination with daratumumab</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Objective response rate with INCB001158 in combination with daratumumab compared to daratumumab monotherapy</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Defined as the proportion of participants with a documented response of partial response (PR) or better, per International Myeloma Working Group (IMWG) criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Defined as the time from the first dose of study drug to the first documented response PR or better, as per IMWG criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Defined as time from first documented response PR or better, as per IMWG criteria, until date of disease progression or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>Defined as the duration from the date of first dose of study drug until either progressive disease (PD), as per IMWG criteria, or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal residual disease</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Defined as the percentage of MRD-negative participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to approximately 3 years</time_frame>
    <description>Defined as the time from the first dose of study drug to the first documented response PR or better, as per IMWG criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Number of treatment-emergent adverse events with INCB001158 as monotherapy at RP2D</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Compare Number of treatment-emergent adverse events of INCB001158 in combination with daratumumab SC to daratumumab SC monotherapy.</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Objective response rate with INCB001158 in combination with daratumumab</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Defined as the proportion of participants with a documented response of partial response (PR) or better, per International Myeloma Working Group (IMWG) criteria</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Relapsed or Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>INCB001158 + daratumumab SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCB001158 + daratumumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daratumumab monotherapy and crossover to INC001158+ daratumumab SC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daratumumab will be administered as monotherapy, once confirmed disease progression participants will be crossed over to INCB001158+daratumumad combination therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INCB001158 monotherapy and crossover to INC001158+ daratumumab SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCB001158 will be administered as monotherapy, once confirmed disease progression participants will be crossed over to INCB001158+daratumumad combination therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB001158</intervention_name>
    <description>Phase 1: INCB001158 administered orally twice daily at the protocol-defined starting dose, with dose escalation/de-escalation based on protocol-defined toxicity criteria to determine the maximum tolerated dose. INCB001158 is administered in combination with daratumumab SC. Phase 2: INCB001158 administered orally at the recommended dose from Phase 1 either as a monotherapy or in combination with daratumumab SC.</description>
    <arm_group_label>INCB001158 + daratumumab SC</arm_group_label>
    <arm_group_label>INCB001158 monotherapy and crossover to INC001158+ daratumumab SC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Daratumumab SC</intervention_name>
    <description>Daratumumab 1800 mg co-formulated with rHuPH20 (2000 U/mL) and administered subcutaneously once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and then once every 4 weeks. Daratumumab will be administered either as monotherapy or in combination with INCB001158.</description>
    <arm_group_label>Daratumumab monotherapy and crossover to INC001158+ daratumumab SC</arm_group_label>
    <arm_group_label>INCB001158 + daratumumab SC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Prior diagnosis of multiple myeloma according to IMWG diagnostic criteria.&#xD;
&#xD;
          -  Measurable disease at screening.&#xD;
&#xD;
          -  Has received at least 3 but not more than 5 prior lines of multiple myeloma treatment,&#xD;
             including proteasome inhibitor, immunomodulatory drug, and anti-CD38 therapies.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status of 0 or 1.&#xD;
&#xD;
          -  Willing to avoid pregnancy or fathering children.&#xD;
&#xD;
          -  Willing to provide fresh and archival bone marrow aspiration and biopsy tissue.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receipt of any of the following treatment within the indicated interval before the&#xD;
             first administration of study drug:&#xD;
&#xD;
               -  Anti-myeloma treatment within 2 weeks or 5 half-lives (whichever is longer).&#xD;
&#xD;
               -  Investigational drug (including investigational vaccines) or invasive&#xD;
                  investigational medical device within 4 weeks.&#xD;
&#xD;
               -  Autologous stem cell transplant within 12 weeks, or allogeneic stem cell&#xD;
                  transplant at any time.&#xD;
&#xD;
               -  Plasmapheresis within 4 weeks.&#xD;
&#xD;
               -  Radiation therapy within 2 weeks.&#xD;
&#xD;
               -  Major surgery within 2 weeks, or inadequate recovery from an earlier surgery, or&#xD;
                  surgery planned during the time the participant is expected to participate in the&#xD;
                  study or within 2 weeks after the last dose of study treatment.&#xD;
&#xD;
          -  Toxicity ≥ Grade 2 from previous anti-myeloma therapy except for stable chronic&#xD;
             toxicities (≤ Grade 2) not expected to resolve, such as stable Grade 2 peripheral&#xD;
             neuropathy.&#xD;
&#xD;
          -  Known additional malignancy (other than multiple myeloma) that is progressing or&#xD;
             requires active treatment, or history of other malignancy within 2 years of study&#xD;
             entry.&#xD;
&#xD;
          -  Laboratory values at screening outside the protocol-defined range.&#xD;
&#xD;
          -  Significant concurrent, uncontrolled medical condition including but not limited to&#xD;
             known chronic obstructive pulmonary disease (COPD), persistent asthma, or history of&#xD;
             asthma within the past 2 years; chronic or current active infectious disease requiring&#xD;
             systemic antibiotics, antifungal, or antiviral treatment; acute diffuse infiltrative&#xD;
             pulmonary disease; clinically significant or uncontrolled cardiac disease.&#xD;
&#xD;
          -  Plasma cell leukemia, Waldenström's macroglobulinemia, POEMS syndrome, or amyloidosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sven Gogov, MD</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southern Cancer Center</name>
      <address>
        <city>Daphne</city>
        <state>Alabama</state>
        <zip>36526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates (Wilmot)</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada - Twain</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lineberger Comprehensive Cancer Center At University of North Carolina Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care, Inc</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Austin Midtown</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Fort Worth South Henderson</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists-Fairfax</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite - Universit�Tsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Munster</name>
      <address>
        <city>Munster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitari Vall D Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic I Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ico Institut Catala D Oncologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon Y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Jimenez Diaz University Hospital</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra (Cun)</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Doctor Peset</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Y Politcnico de La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 7, 2019</study_first_submitted>
  <study_first_submitted_qc>February 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2019</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Arginase inhibitor</keyword>
  <keyword>multiple myeloma</keyword>
  <keyword>Daratumumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Daratumumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

